Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

232.48USD
22 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$232.48
Open
--
Day's High
--
Day's Low
--
Volume
17,200
Avg. Vol
837,431
52-wk High
$388.67
52-wk Low
$216.13

Select another date:
Photo

Biogen profit rises 72% on multiple sclerosis therapy sales

Biogen Inc posted a 72% rise in quarterly profit and lifted its 2019 earnings forecast on Tuesday, boosted by higher sales of its top-selling multiple sclerosis therapy Tecfidera.

Biogen profit rises 72% on multiple sclerosis therapy sales

Biogen Inc posted a 72% rise in quarterly profit and lifted its 2019 earnings forecast on Tuesday, boosted by higher sales of its top-selling multiple sclerosis therapy Tecfidera.

UPDATE 1-Biogen profit rises 72% on multiple sclerosis therapy sales

July 23 Biogen Inc posted a 72% rise in quarterly profit and lifted its 2019 earnings forecast on Tuesday, boosted by higher sales of its top-selling multiple sclerosis therapy Tecfidera.

Biogen profit rises 72%

July 23 Drugmaker Biogen Inc reported a 72.4% rise in second-quarter profit on Tuesday, boosted by higher sales of its multiple sclerosis treatment Tecfidera and lower research and development costs.

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

UPDATE 1-NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

Select another date: